About Pharmacovigilance 2014
Current Complexities, Controversies, and Hot Topics in Pharmacovigilance and Risk Management
This global three-day program will provide new insights into the current issues and associated challenges impacting drug safety, focusing primarily on drug products and biologics, throughout all phases of development and marketed use.Top pharmaceutical, biotechnology, and regulatory thought leaders convene each January to discuss new and updated legislation in various ICH regions, current regulatory framework for pharmacovigilance in global regions, operational challenges of implementing global Benefit-risk analyses and risk management plans, the impact of social media, and the role of epidemiology in safety analysis.
John S. Brownstein, PhD
Manager and Associate Professor
Boston Children's Hospital and Harvard Medical School
Who Should Attend?
Intermediate to Advanced Clinical Safety Professionals who are involved in:
- Drug Safety/Pharmacovigilance
- Risk Management
- Medical Product Safety Assessment
- Regulatory Affairs
- Clinical Research
- Data Analysis
- Medical Information
- Health Outcomes
It is also designed for professionals who work for:
- Industry: Pharmaceuticals and Biologics
- Clinical Research Organizations (CROs)
- Academic Research Centers
- Regulatory Agencies
“When I attend the DIA meetings, I feel that I am with my family.” - 2013 Attendee
“This conference offers a good overview of everything going on regard PV/RMP globally and is also very useful for people like me in Global Medical Affairs who are contributors and collaborators with PV/RMP groups” - Dr. Claudia Schoenig-Diesing, Baxter Healthcare Corp.
“Great program. Helps to stay on the top of new regulations.” - Cherif Benattia, Sunovion